Status:
WITHDRAWN
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Lead Sponsor:
University of California, Irvine
Collaborating Sponsors:
American College of Radiology Imaging Network
Massachusetts General Hospital
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. Th...
Detailed Description
The investigators are testing the effectiveness of an experimental imaging technology known as Diffuse Optical Spectroscopy Imaging in predicting the success of chemotherapy treatment (shrinkage of tu...
Eligibility Criteria
Inclusion
- Female, 18 years of age or older, non pregnant or nursing.
- Diagnosis of breast cancer and will be receiving chemo therapy treatments
Exclusion
- 18 years of age or younger, pregnant or nursing.
- Previous treatment including chemo therapy, radiation, surgery, and hormone therapy.
- Previous diagnosis with other form of cancer.
Key Trial Info
Start Date :
December 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01257932
Start Date
December 1 2010
End Date
October 1 2013
Last Update
November 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beckman Laser Institute
Irvine, California, United States, 92612